论文部分内容阅读
目的:对比美能与思美泰治疗妊娠合并HBV病毒感染后肝功能及凝血指标的变化。方法:116例妊娠合并HBV病毒感染患者随机分成美能组和思美泰组各58例。于治疗前后分别测定患者血清丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、血清总胆红素(TBIL)、总胆汁酸(TBA)水平以及血浆凝血酶原时间(PT)、活化的部分凝血活酶时间(APTT),并对妊娠结局进行汇总。结果:两组患者治疗后,血清ALT、AST、TBIL以及TBA均明显下降(P<0.05),且美能组ALT、AST、PT下降幅度大于思美泰组(P<0.05),美能组PT明显缩短(P<0.05),两组妊娠结局比较无统计学差异。结论:美能治疗妊娠合并HBV病毒感染患者,可以更好地改善患者的肝功能和凝血功能,对孕妇和胎儿影响小,值得在临床工作中加以推广应用。
OBJECTIVE: To compare the changes of liver function and coagulation index after treatment of pregnant women complicated with HBV infection by MEBO and Smectite. Methods: A total of 116 patients with HBV infection during pregnancy were randomly divided into two groups, 58 cases in each group. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total serum bilirubin (TBIL), total bile acid (TBA) and plasma prothrombin time (PT), activated partial thromboplastin time (APTT), and summary of pregnancy outcomes. Results: After treatment, serum ALT, AST, TBIL and TBA were significantly decreased in both groups (P <0.05), and the decrease of ALT, AST and PT in the Ameng group was greater than that in the Simmel group (P <0.05) Shortened (P <0.05), no significant difference in pregnancy outcome between the two groups. Conclusion: MEng can treat patients with hepatitis B virus infection during pregnancy can improve the liver function and coagulation function of patients better. It has less impact on pregnant women and fetus and should be popularized and applied in clinical work.